Non-insulin dependent diabetes in children and adolescents: The therapeutic challenge

Clinical Pediatrics

Volumn 37, Issue 2, 1998, Pages 103-110

  Jones, Kenneth Lee ^a,b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; INSULIN; METFORMIN; SULFONYLUREA DERIVATIVE;

ACANTHOSIS NIGRICANS; ADOLESCENT; CASE REPORT; CONFERENCE PAPER; DIABETIC DIET; DIABETIC KETOACIDOSIS; ETHNIC GROUP; EXERCISE; FAMILY HISTORY; FEMALE; HUMAN; INCIDENCE; JUVENILE DIABETES MELLITUS; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT COUNSELING; RISK FACTOR; TREATMENT PLANNING;

EID: 0031939331     PISSN: 00099228     EISSN: None     Source Type: Journal    
DOI: 10.1177/000992289803700207     Document Type: Conference Paper

References (50)

1. Harris MI, Hadden IWC, Knowler VVC, et al. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S. populations aged 20-74 years. Ditibetes. 1987;36:523-534.
2. Banerji MA, Lebovitz HE. Insulin-sensitive and insulin-resistant variants in NIDDM. Diabetes. 1989;38:784-792.
3. Arner P, Pollare T, Litthell H. Different aetiologies of type 2 (non-insulin dependent) diabetes mellitus in obese and non-obese subjects. Diabetologia, 1991;34:483-487.
4. Hales CN, The pathogensis of NIDDM. Diabetologia. 1994;37(suppl):162-168.
5. Polonsky KS. The β-cell ni diabetes: from molecular genetics 10 clinical research. Diabetes. 1995;44:707-717.
6. Harris MI. Epidemiological correlates of NIDDM in Hispanics, whites, and blacks in the U.S. population. Diabetes Care. 1994;17:1337-1340.
7. Gardner LI, Stern MP, Hazuda HP, et al. Prevalence of diabetes in Mexican Americans. Diabetes. 1983;33:86-92.
8. Raboudi SH, Mitchel BD, Stern MP, el al. Type II diabetes mellitus and polymorphism of insulin-receptor gene in Mexican Americans. Diabetes. 1989;38:975-980.
9. Bogardus C. Insulin resistance in the pathogenesis of NIDDM in Pima Indians, Diabetes Care. 1993;16:228-231.
10. The DCCT Research Group, Diabetes Control and Complications Trial (DCCT): Results of Feasibility Study, Diabetes Care. 1987;10:1-19.
11. Neufeld N, Raffel L, Landon C, et al. (Childhood onset of type II diabetes mellitus in Hispanic Americans (abstract). Clin Res. 1993;40:70.
12. Franz MJ, Horton ES, Bantle JP, et al. Nutritional principles for the management of diabetes and related complications. Diabetes Care. 1994;17:490-518.
13. Jenkins DJA, Wolever TMS, Ocana AM, et al. Metabolic effects of reducing rate of glucose ingestion by single bolus versus continuous sipping, Diabete. 1990;39:775-781.
14. Jenkins DJA, Wolever TMS, Vuksan V, et al. "Nibbling versus gorging": metabolic advantages of increased meal frequency, N Engl J Med. 1989;321:929-934.
15. Lebovitz HE. Oral antidiabetic agents. In: Kahn CR, Weir GC, eds. Joslin;s Diabetes Mellitus Philadelphia: Waverly; 1994:508-529.
16. Kolterman OG, Gray RX, Shapiro G, el al. The acute and chronic effects of sulfonylurea therapy in type II diabetic subjects. Diabetes. 1984;33:346-354.
17. Gerich JE, Oral hypoglycemic agents, N Engl J Med. 1989;321:1231-1245.
18. Aguilar-Bryan L, Nichols CG, Wechsler SW, et al. Cloning of the β-cell high-affinity sulfonylurea receptor: a regulator of insulin secretion. Science. 1995;268:423-426.
19. Fajans SS. Scope and heterogeneous nature of MODY. Diabetes Care. 1990;13:40-64.
20. Groop LC, Pelkinen R, Koskimies S, et al. Secondary failure to treatment with oral antidiabetie agents in noninsulin dependent diabetes, Diabetes Care. 1986;9:129-133.
21. Reaven GM. Banting Lecture 1988: role of insulin resistance in human disease. Diabetes. 1988;37:1595-1607.
22. Duckworth WC, Solomon SS, Kitabchi AE. Effects of chronic sulfonylurea therapy on plasma insulin and proinsulin levels. J Clin Endoerinol. 1972;35:585-591.
23. Ferner RE, Neil HAW. Sulphonylureas and hypoglycaemia, Br Med J. 1988; 296:949-950.
24. Lucin OJ. The status of metformin in Canada. Can Med Assoc J. 1983;128:24-26.
25. Vigneri R, Goldfine ID. Rote of metformin in treatment of diabetes mellitus, Diabetes Care. 1987;10:118-122.
26. Marchetti P, Navalesi R, Pharmacoki-netic-pharmacodynamic relationships of oral hypoglycaemic agents: an update. Clin Pharmacokinct. 1989;16:100-128.
27. Stumvoll M, Nurjhan N, Periello G, et al. Metabolic effects of metformin in non-insulin dependent diabetes mellitus, N Engl J Med. 1995;333:550-554.
28. Campbell IW, Menzies DG, Chalmers J, et al. One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. Diabetes Metab. 1994; 20:394-400.
29. DeFronzo RA, Goodman AM, Multicenter Metformin Study Group, Efficacy of metformin in patients with non-insulin dependent diabetes mellitus. N Engl J Med. 1995;333:541-549.
30. Bischoff H. Pharmacology of α-glucosidase inhibition, Eur J Clin Invest. 1994;3:3-10.
31. Chiasson JL, Josse RG, Hum JA, et al. The efficacy of acarbose in the treatment of patients with non-insulin dependent diabetes mellitus. A multicenter controlled clinical trial. Ann Intern Med. 1994;121:928-935.
32. Coniff RF, Shapiro JA, Seaton TB, et al. Multicenter, placebo-controlled trial comparing acarbose with placebo, tolbutamide, and tolbutamide-plusacarbose in non-insulin dependent diabetes mellitus. Am J Med. 1995;98:443-451.
33. Coniff RF, Shapiro JA, Robbins D, et al. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study. Diabetes Care. 1995;18:817-824.
34. Balfour JA, McTavish D. Acarbose. An update of its pharmacology and therapeutic use in diabetes mellitus. Drugs. 1995;46:1023-1054.
35. The DCCT Research Group, The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
36. Reaven GM. Role of insulin resistance in human disease, Diabetes. 1988;37:1595-1607.
37. Caro JF. Insulin resistance in obese and non obese men. J Clin Endocrinol Metab. 1991;73:69l-695.
38. Henry RR, Gumbiner B, Ditzler T, et al. Intensive conventional insulin therapy for type II diabetes. Metabolic effects during a 6-month outpatient trial. Diabetes Care. 1993;16:21-31.
39. Abraira C, Johnson N, Colwell J, et al. VA cooperative study on glycemic control and complications in type II diabetes (VACSCM). Diabetes Care. 1995;18:1113-1123.
40. Turner RC, Phillips MA, Ward EA. Ultralente based insulin regimens - clinical advantages and disadvantages. Acta Med Scand. 1983;671(suppl):75-86.
41. Henry RR, Gumbiner B, Ditzler T, et al. intensive conventional insulin therapy for type II diabetes: metabolic effects during a 6-month outpatient trial. Diabetes Care. 1993;16:21-31.
42. Riddle MC. Evening insulin strategy. Diabetes Care. 1990;13:676-686.
43. Genuth S. Insulin use in NIDDM. Diabetes Care. 1990;13:1240-1260.
44. Turner RC, Holman RR. Insulin use in NIDDM; rationale based on pathophysiology of disease. Diabetes Care. 1990;13:1011-1020.
45. Edelman SV, Henry RR. Insulin therapy for normalizing glycosylated hemoglobin in type II diabetes. Diabetes Rev. 1995;3:308-334.
46. Suter SL, Nolan JJ, Wallace P, et al. Metabolic effects of new oral hypoglycemic agents CS-045 in NIDDM subjects. Diabetes Care. 1992;15:192-203.
47. Saltier AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes. 1996;45:1661-1669.
48. Iwamoto Y, Kuzuya T, Matsuda A, et al. Effect of new oral antidiabetic agents CS045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care. 1991;14:1083-1086.
49. Suter SL, Nolan JJ, Wallace P, et al. Metabolic effects of new oral hypoglycemic agents CS-045 in NIDDM subjects. Diabetes Care. 1992;15:193-203.
50. Kumar S, Boulton AJM, Beck-Nielsen H, et al. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Diabetologia. 1996;39:701-709.